Related Experiment Video
Updated: Oct 17, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Comparison of pivmecillinam and cephalexin in acute uncomplicated urinary tract infection
1Leo Pharmaceuticals, Princes Risborough, Bucks, UK. paul.menday@leo-pharma.com
Abstract:
The clinical and bacteriological efficacy of a 3-day course of pivmecillinam, 200 mg three times daily, was compared with that of a 7-day course of cephalexin, 250 mg four times daily, in 216 patients with a bacteriologically confirmed, acute, uncomplicated, urinary tract infection. Both treatments were similarly effective. Clinical cure or improvement was obtained in 95.3% of patients given pivmecillinam and in 93.6% of patients given cephalexin. Bacteriological success was achieved in 89.7 and 81.7% patients taking pivmecillinam or cephalexin, respectively. Eradication rates for Escherichia coli were 90.1% for pivmecillinam and 80.6% for cephalexin. Both treatments were well tolerated. This study has confirmed that a 3-day course of pivmecillinam is effective and well tolerated in uncomplicated cystitis.
Insights
A 3-day course of pivmecillinam effectively treats uncomplicated urinary tract infections, showing comparable results to a 7-day cephalexin regimen. This short-course antibiotic therapy is well-tolerated and a viable option for acute cystitis.
Area of Science:
- Infectious Diseases
- Pharmacology
- Urology
Background:
- Urinary tract infections (UTIs) are common, often caused by Escherichia coli.
- Short-course antibiotic regimens are desirable to improve patient compliance and reduce side effects.
- Pivmecillinam is an antibiotic effective against common UTI pathogens.
Purpose of the Study:
- To compare the clinical and bacteriological efficacy of a 3-day pivmecillinam course versus a 7-day cephalexin course for acute, uncomplicated UTIs.
- To assess the tolerability of both treatment regimens.
Main Methods:
- A randomized clinical trial involving 216 patients with bacteriologically confirmed UTIs.
- Patients received either pivmecillinam (200 mg TID for 3 days) or cephalexin (250 mg QID for 7 days).
- Clinical and bacteriological outcomes, including Escherichia coli eradication, were evaluated.
Main Results:
- Clinical cure/improvement rates were high for both groups: 95.3% for pivmecillinam and 93.6% for cephalexin.
- Bacteriological success rates were 89.7% for pivmecillinam and 81.7% for cephalexin.
- Escherichia coli eradication rates were 90.1% for pivmecillinam and 80.6% for cephalexin. Both treatments were well tolerated.
Conclusions:
- A 3-day course of pivmecillinam is clinically and bacteriologically effective for uncomplicated cystitis.
- Pivmecillinam offers a well-tolerated, shorter treatment option compared to standard cephalexin regimens.
- Short-course pivmecillinam demonstrates high efficacy, particularly against Escherichia coli, in treating acute UTIs.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Urine Studies II: Urine Culture and Sensitivity Test
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Urinary Tract Infection I: Introduction
Acute Pyelonephritis I: Introduction
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care